Document ID: chunk:federal_register_of_legislation:F2024C01104:reg:5a:p3
Version: federal_register_of_legislation:F2024C01104
Segment Type: reg
Provision Reference: reg 5A (pt 3/3)
Character Range: 12094–12993

frequency depending on age, weight and severity of condition, length of treatment, suitable titration, and interactions with other medicines; and
 (e) provide contact details about smoking cessation support services to the patient; and
 (f) if the pharmacist becomes aware that the patient has suffered an adverse event in relation to the therapeutic good—notify the Therapeutic Goods Administration and the sponsor of the therapeutic good about the adverse event in accordance with the reporting guidelines set out in the SAS Guidance; and
 (g) if the pharmacist becomes aware of a defect in the therapeutic good—notify the Therapeutic Goods Administration and the sponsor of the therapeutic good in accordance with the reporting guidelines set out in the SAS Guidance.
 (7) The pharmacist must store the therapeutic good in a part of the pharmacy premises to which the public does not have access.